The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Scientific presentation selector
Geo Regions
Important Notice Regarding the Scientific Information You Have Requested
You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven.
Please acknowledge that you understand this before proceeding.
BackImportant Notice: The information provided here relates to investigational therapies. The safety and efficacy of these investigational therapies has not been proven.
Poster
Exposure-Response Characterization of the Safety Profile for a Novel KAT6 Inhibitor, PF-07248144, For Use In Dose Optimization During a Phase 1 First-in-Patient Study
Liyanage M, Kowalski K, Williams JH, Huynh D, Li M, Masters JC
Prifetrastat (PF-07248144) | October 20, 2025 | ACoP 2025
C4551001 | NCT04606446
Poster
Model-Informed Recommended Phase 3 Dose for a novel KAT6 inhibitor, PF-07248144, Following Dose Optimization in 2L+ ER+/HER2- Metastatic Breast Cancer (mBC) population
Kowalski K, Liyanage M, Jermain B, Hahn E, Hee B, Pithavala Y, Li M, Masters J
Prifetrastat (PF-07248144) | September 15, 2025 | ACCP 2025
C4551002 | NCT07062965
Presentation
Dose optimization of PF-07248144, a first-in-class KAT6 inhibitor, in patients with ER+/HER2− metastatic breast cancer: results from phase 1 study to support the recommended phase 3 dose
LoRusso P, Mukohara T, Sommerhalder D, Yonemori K, Hamilton E, Layman RM, Kim SB, Im SA, Rugo HS, Yamashita T, Yan F, Hara F, Kim G, Wang S, Kent S, Liu L, Skoura A, Kowalski K, Li M, Park YH
Prifetrastat (PF-07248144) | May 30, 2025 | ASCO 2025
C4551001 | NCT04606446
Presentation
A phase 1 dose expansion study of a first-in-class KAT6 inhibitor — PF-07248144 in patients with advanced or metastatic ER+ HER2− breast cancer
Mukohara T, Park YH, Sommerhalder D, Yonemori K, Kim SB, Kim H, Iwata H, Yamashita T, Layman RM, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M, Mishra NH, Maity AK, Bogg O, Meng Li M, LoRusso PM
Prifetrastat (PF-07248144) | June 1, 2024 | ASCO 2024
C4551001 | NCT04606446